NEW YORK, April 29, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced that Kapil Dhingra, M.D., has been named chairman of Exosome Diagnostics Board of Directors.
Dr. Dhingra, 52, has served as a member of Exosome's board of directors since March 2012. He has significant experience transforming oncology therapeutic and diagnostic development programs into products available to physicians and patients. He is managing member of KAPital Consulting, a healthcare consulting firm he founded in 2008, which provides oncology-related strategic consulting services to biopharmaceutical companies. From 1999-2008, he served in positions of increasing responsibility at Hoffmann-La Roche, Inc, including vice president, head, Oncology Disease Biology Leadership team and Head, Oncology Clinical Development. Before joining Roche, he worked at Eli Lilly & Co, and on the faculty of The University of Texas MD Anderson Cancer Center. During his tenures at both Eli Lilly and Hoffmann-LaRoche, Dr. Dhingra maintained an active academic career first as a clinical associate professor at Indiana University School of Medicine and most recently as a Clinical Affiliate at Memorial Sloan Kettering Cancer Center. Dr. Dhingra also serves on several emerging life science company boards. He previously served on the Boards of several successful companies, including Biovex, Micromet and YM Biosciences, that were acquired by major pharmaceutical companies. He received his medical training from the All India Institute of Medical Sciences.
"Dr. Dhingra has been a critical contributor to the company since he was first appointed to our Board of Directors last year," said James McCullough , chief executive officer of Exosome D
|SOURCE Exosome Diagnostics|
Copyright©2012 PR Newswire.
All rights reserved